Inactive Instrument

TearLab Corporation

Medical Equipment, Supplies & Distribution

TearLab Corporation Announce Board Changes

January 18, 2018 at 04:01 pm

On January 16, 2018, Mr. Thomas Davidson, Jr., Dr. Adrienne Graves, Mr. Donald Rindell and Dr. Brock Wright resigned as members of TearLab Corporation’s Board of Directors.

Latest news about TearLab Corporation

TearLab Corporation Announces Board Appointments	21-12-09	CI
TearLab Corporation Appoints Adam Szaronos as Chief Executive Officer	21-12-09	CI
Tearlab Corporation Appoints James V. Mazzo to the Company's Board of Directors	21-11-09	CI
MellingMedical and TearLab Agreement Aims to Enhance Early Detection of Dry Eye Disease in American Veterans	21-09-16	CI
TearLab Appoints Adam Szaronos as Chief Commercial Officer	20-07-28	CI
Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) completed the acquisition of TearLab Corporation.	20-07-08	CI
TearLab Corporation to Seek Acquisitions	20-07-08	CI
Tearlab Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020	20-06-26	CI
TearLab Corporation Announces Board Appointments	20-05-11	CI
Tearlab Mulls Inorganic Growth Opportunities	20-05-11	CI
TearLab Corporation announced that it expects to receive $25 million in funding from Accelmed Fund	20-05-10	CI
Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) entered into term sheet to acquire TearLab Corporation for $0.74 million.	20-05-10	CI
TearLab Corporation Resubmits 510(k) for U.S. FDA Clearance of the TearLab Discovery™ MMP-9 Test	20-04-22	CI
TearLab Corporation Announces Amendment to Loan Agreement	20-04-07	CI
TearLab Corporation Auditor Raises 'Going Concern' Doubt	20-03-05	CI
Tearlab Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2019	20-03-05	CI
Tearlab Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-08	CI
TearLab Corporation Enters into an Amendment to Its Term Loan Agreement	19-10-08	CI
Tearlab Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-08	CI
Tearlab Corporation Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-10	CI
TearLab Corporation Auditor Raises 'Going Concern' Doubt	19-03-21	CI
Tearlab Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2018	19-03-21	CI
TearLab Corporation Announces Amendment to Loan Agreement	18-11-13	CI
Tearlab Corporation Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018	18-11-07	CI
Tearlab Provides Update on 510(k) for U.S. FDA Clearance of Discovery MMP-9 Test	18-10-11	CI

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc., develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. Its product, the TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor's office. The TearLab Osmolarity System consists of approximately three components: the TearLab disposable, the TearLab Pen, and the TearLab Reader. The TearLab disposable is a single-use microfluidic microchip. The TearLab Pen is a hand-held device that interfaces with the TearLab disposable. The TearLab Reader is a small desktop unit that allows for the docking of the TearLab Pen.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Glasses, Spectacles & Contact Lenses

	1st Jan change	Capi.
ESSILORLUXOTTICA	+14.65%	103B
ALCON INC.	+24.95%	44.74B
THE COOPER COMPANIES, INC.	+0.30%	18.77B
AUTEK CHINA INC.	-19.66%	2.27B
PEGAVISION CORPORATION	+19.92%	1.16B
MINGYUE OPTICAL LENS CO.,LTD.	-37.43%	729M
UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.	-7.94%	670M
MENICON CO., LTD.	-42.78%	663M
SHANGHAI CONANT OPTICAL CO., LTD.	+33.43%	490M

Glasses, Spectacles & Contact Lenses